Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial
Erik Johnsen, Rune A. Kroken, Else‐Marie Løberg, Maria A. Rettenbacher, Inge Joa, Tor Ketil Larsen, Solveig Klæbo Reitan, Berit Walla, Renata Alisauskiene, Liss Anda, Christoffer Bartz‐Johannessen, Jan Øystein Berle, Jill Bjarke, Farivar Fathian, Kenneth Hugdahl, Eirik Kjelby, Igne Sinkeviciute, Silje Skrede, Lena Antonsen Stabell, Vidar M. Steen, W. Wolfgang Fleischhacker
Topics & Concepts
AmisulprideAripiprazoleOlanzapineMedicinePositive and Negative Syndrome ScalePopulationRandomized controlled trialSchizophrenia (object-oriented programming)PsychiatryRisperidoneInternal medicinePsychologyPediatricsPsychosisEnvironmental healthSchizophrenia research and treatmentMental Health and PsychiatryHealthcare Decision-Making and Restraints